← Back to headlines
Tarsus Projects $670M–$700M 2026 Sales, XDEMVY Eyes $2B+ Potential
Tarsus expects 2026 sales between $670 million and $700 million, with its drug XDEMVY projected to reach over $2 billion in potential sales as its pipeline advances.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
